1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/22035
Full metadata record
DC FieldValueLanguage
dc.contributor.authorFlorentin, M.en
dc.contributor.authorKostapanos, M. S.en
dc.contributor.authorNakou, E. S.en
dc.contributor.authorElisaf, M. S.en
dc.contributor.authorLiberopoulos, E. N.en
dc.date.accessioned2015-11-24T19:20:23Z-
dc.date.available2015-11-24T19:20:23Z-
dc.identifier.issn1940-4034-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/22035-
dc.rightsDefault Licence-
dc.subjectAnti-Obesity Agents/*administration & dosageen
dc.subjectAnticholesteremic Agents/*administration & dosageen
dc.subjectAzetidines/*administration & dosageen
dc.subjectBody Weight/drug effectsen
dc.subjectDrug Therapy, Combination/adverse effectsen
dc.subjectDyslipidemias/complications/*drug therapyen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectHydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic useen
dc.subjectLactones/*administration & dosageen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectObesity/complications/*drug therapyen
dc.subjectOverweight/complications/*drug therapyen
dc.subjectPiperidines/*administration & dosageen
dc.subjectPyrazoles/*administration & dosageen
dc.titleEfficacy and safety of ezetimibe plus orlistat or rimonabant in statin-intolerant nondiabetic overweight/obese patients with dyslipidemiaen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1177/1074248409343935-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/19724023-
heal.identifier.secondaryhttp://cpt.sagepub.com/content/14/4/274.full.pdf-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2009-
heal.abstractAIMS: To compare the effects of ezetimibe plus orlistat or rimonabant on anthropometric and lipid parameters in nondiabetic statin-intolerant overweight/obese patients with dyslipidemia. METHODS AND RESULTS: Thirty participants received a hypocaloric diet and were randomized to open-label combination of ezetimibe (10 mg/day) with orlistat (120 mg, 3 times a day with meals; ezetimibe/orlistat [EO], n = 15) or rimonabant (20 mg/day; ezetimibe/rimonabant [ER], n = 15). Anthropometric and metabolic variables were assessed at baseline and 3 months posttreatment. Similar reductions in body weight, body mass index, and waist circumference were recorded in both groups (-8.3%, -8.6%, and -5.2% in the EO group and -7.3%, -7.2%, and -7.0% in the ER group, P < .01 vs baseline for all). Low-density lipoprotein cholesterol (LDL-C) levels decreased in both treatment groups, but this reduction tended to be more pronounced in the EO group (28.4% vs 15.3%, respectively; P < .01 vs baseline for both). Triglycerides tended to decrease more in the ER compared with the EO group (-20.4% vs -14.1%, P < .01 vs baseline for both). High-density lipoprotein cholesterol (HDL-C) levels tended to decrease in EO group, but remained unaltered with ER treatment. Apolipoprotein B levels were equally reduced in both treatment groups. CONCLUSION: For similar body weight reduction, the combination of ezetimibe with orlistat may be more efficient in LDL-C lowering, whereas the combination of ezetimibe with rimonabant may be more potent in terms of improving HDL-C and triglycerides.en
heal.journalNameJ Cardiovasc Pharmacol Theren
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
File Description SizeFormat 
Florentin-2009-Efficacy and safety.pdf156.73 kBAdobe PDFView/Open    Request a copy
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons